RPRX..$9.13..Repros Reports Both Primary Endpoints Successfully Met in First Pivotal Study of Androxal. Conference Call tomorrow morning! http://yhoo.it/16Z9DCv
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.